Cargando…
Effect of in vivo Hydroxychloroquine and ex vivo Anti-BDCA2 mAb Treatment on pDC IFNα Production From Patients Affected With Cutaneous Lupus Erythematosus
Objective: Plasmacytoid dendritic cells (pDCs) are a major source of Type-I Interferon (IFN-I), a key driver in cutaneous lupus erythematosus (CLE). Currently evaluated in Phase II clinical trial, 24F4A (BIIB059) is an antibody targeting BDCA2, an inhibitory receptor expressed on pDCs. Given that Hy...
Autores principales: | Gardet, Agnes, Pellerin, Alex, McCarl, Christie-Ann, Diwanji, Rohan, Wang, Wenting, Donaldson, Douglas, Franchimont, Nathalie, Werth, Victoria P., Rabah, Dania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394354/ https://www.ncbi.nlm.nih.gov/pubmed/30846987 http://dx.doi.org/10.3389/fimmu.2019.00275 |
Ejemplares similares
-
Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo
por: Wrzesinski, Stephen H, et al.
Publicado: (2013) -
BDCA1(+) cDC2s, BDCA2(+) pDCs and BDCA3(+) cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients
por: Sosa Cuevas, Eleonora, et al.
Publicado: (2020) -
Implications of post-translational modifications of IRF7 on pDC IFN-alpha response
por: Griesbeck, M, et al.
Publicado: (2012) -
pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation
por: Duraes, Fernanda V., et al.
Publicado: (2016) -
Ribavirin Contributes to Hepatitis C Virus Suppression by Augmenting pDC Activation and Type 1 IFN Production
por: Wang, Yang, et al.
Publicado: (2015)